A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in
multiple myeloma patients.
To determine the overall response rate (CR+PR) of patients with relapsed or refractory
multiple myeloma treated with Thymoglobulin.
To determine the time to response, duration of response, and time to progression and overall
survival of patients treated with Thymoglobulin.
To determine the safety and tolerability of Thymoglobulin in these patients.
To assess the changes in lymphocyte apoptosis and apoptotic signaling in treated patients.